Acadia: Big News On The Near Horizon


  • Acadia reported solid earnings for Q3, 2021 despite COVID-19 headwind lashing its Parkinson’s Disease Psychosis [PDP] earnings.
  • Acadia’s completed Type A Meeting with the FDA has opened the door for a targeted next step.
  • NUPLAZID approval in treatment of Alzheimer’s Disease [ADP] would be a big deal and is a real near-term possibility.
  • Acadia has released positive data on its pivotal Lavender trial for trofinetide, its experimental Rett syndrome therapy.
Plus and minus or positive and negative symbols on wooden blocks are in balance on a wooden seesaw

cagkansayin/iStock via Getty Images

Over the last year, ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have taken a real licking, those hardy souls who have endured the pain may soon feel that Acadia will go on ticking. During its Q3, 2021 earnings call, (the “Call”) Acadia signaled important

Disclosure: I/we have a beneficial long position in the shares of ACAD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I may buy or sell shares in Acadia over the next 72 hours.

Leave a Reply

Your email address will not be published. Required fields are marked *